Background/Purpose: Polymethylmethacrylate (PMMA) and calcium phosphate (Ca-P) cements are widely used for arthroplasty surgery and augmentation of bone defects. However, aseptic implant loosening in absence of wear-induced osteolysis indicates an unfavourable interaction between the cement surface and human osteoblasts. Our underlying hypothesis is that cement surfaces directly modify cell viability, proliferation rate, and cell differentiation. Methods: To test this hypothesis, we examined primary human osteoblasts harvested from six individuals. These cells were pooled and subsequently seeded directly on cement pellets prepared from Palacos® R, Palacos® R+G, and Norian® Drillable cements. After incubation for 24 and 72 h, cell viability, proliferation rate, apoptosis rate, and cell differentiation were analysed. Results: Upon cultivation of human osteoblasts on cement surfaces, we observed a significantly reduced cell viability and DNA content compared to the control. Analysis of the apoptosis rate revealed an increase for cells on Palacos R and Norian Drillable, but a significant decrease on Palacos R+G compared to the control. Regarding osteogenic differentiation, significantly lower values of alkaline phosphatase enzyme activity were identified for all cement surfaces after 24 and 72 h compared to cultivation on tissue culture plastic, serving as control. Conclusions: In summary, these data suggest a limited biocompatibility of both PMMA and Ca-P cements, necessitating further research to reduce unfavourable cell-cement interactions and consequently extend implant survival.

Keywords:
Bone marrow, Polymethylmethacrylate, Calcium phosphate, Primary human osteoblast, Biocompatibility
1.
Jakob M, Saxer F, Scotti C, Schreiner S, Studer P, Scherberich A, Heberer M, Martin I: Perspective on the evolution of cell-based bone tissue engineering strategies. Eur Surg Res 2012;49:1-7.
2.
Lobenhoffer P, Gerich T, Witte F, Tscherne H: Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures: a prospective study of twenty-six cases with twenty-month mean follow-up. J Orthop Trauma 2002;16:143-149.
3.
Zimmermann G, Moghaddam A: Allograft bone matrix versus synthetic bone graft substitutes. Injury 2011;42(suppl 2):S16-S21.
4.
Everts PA, Jakimowicz JJ, van Beek M, Schonberger JP, Devilee RJ, Overdevest EP, Knape JT, van Zundert A: Reviewing the structural features of autologous platelet-leukocyte gel and suggestions for use in surgery. Eur Surg Res 2007;39:199-207.
5.
Rueger JM: Bone substitution materials. Current status and prospects (in German). Orthopade 1998;27:72-79.
6.
Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA: Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996;329:300-309.
7.
Banwart JC, Asher MA, Hassanein RS: Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine (Phila Pa 1976) 1995;20:1055-1060.
8.
Silber JS, Anderson DG, Daffner SD, Brislin BT, Leland JM, Hilibrand AS, Vaccaro AR, Albert TJ: Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 2003;28:134-139.
9.
Summers BN, Eisenstein SM: Donor site pain from the ilium. A complication of lumbar spine fusion. J Bone Joint Surg Br 1989;71:677-680.
10.
Henkel KO, Gerber T, Dorfling P, Hartel J, Jonas L, Gundlach KK, Bienengraber V: Stimulating regeneration of bone defects by implantation of bioceramics and autologous osteoblast transplantation (in German). Mund Kiefer Gesichtschir 2002;6:59-65.
11.
Zhang J, Liu W, Schnitzler V, Tancret F, Bouler JM: Calcium phosphate cements for bone substitution: chemistry, handling and mechanical properties. Acta Biomater 2014;10:1035-1049.
12.
Brown TE, Harper BL, Bjorgul K: Comparison of cemented and uncemented fixation in total knee arthroplasty. Orthopedics 2013;36:380-387.
13.
Becker S, Meissner J, Bartl R, Bretschneider W, Ogon M: Preliminary results with modified techniques of balloon kyphoplasty for vertebra plana, traumatic fractures and neoplasms. Acta Orthop Belg 2006;72:187-193.
14.
Blattert TR, Jestaedt L, Weckbach A: Suitability of a calcium phosphate cement in osteoporotic vertebral body fracture augmentation: a controlled, randomized, clinical trial of balloon kyphoplasty comparing calcium phosphate versus polymethylmethacrylate. Spine (Phila Pa 1976) 2009;34:108-114.
15.
Postl LK, Ahrens P, Beirer M, Cronlein M, Imhoff AB, Foehr P, Burgkart R, Braun C, Kirchhoff C: Pull-out stability of anchors for rotator cuff repair is also increased by bio-absorbable augmentation: a cadaver study. Arch Orthop Trauma Surg 2016;136:1153-1158.
16.
Moreau MF, Chappard D, Lesourd M, Montheard JP, Basle MF: Free radicals and side products released during methylmethacrylate polymerization are cytotoxic for osteoblastic cells. J Biomed Mater Res 1998;40:124-131.
17.
Vale FM, Castro M, Monteiro J, Couto FS, Pinto R, Giao Toscano Rico JM: Acrylic bone cement induces the production of free radicals by cultured human fibroblasts. Biomaterials 1997;18:1133-1135.
18.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
19.
Liu D, Li C, Chen Y, Burnett C, Liu XY, Downs S, Collins RD, Hawiger J: Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. J Biol Chem 2004;279:48434-48442.
20.
Aubin JE, Liu F, Malaval L, Gupta AK: Osteoblast and chondroblast differentiation. Bone 1995;17(2 suppl):77S-83S.
21.
Isama K, Tsuchiya T: Enhancing effect of poly(L-lactide) on the differentiation of mouse osteoblast-like MC3T3-E1 cells. Biomaterials 2003;24:3303-3309.
22.
Pauksch L, Hartmann S, Szalay G, Alt V, Lips KS: In vitro assessment of nanosilver-functionalized PMMA bone cement on primary human mesenchymal stem cells and osteoblasts. PLoS One 2014;9:e114740.
23.
Palmer I, Nelson J, Schatton W, Dunne NJ, Buchanan FJ, Clarke SA: Biocompatibility of calcium phosphate bone cement with optimized mechanical properties. J Biomed Mater Res B Appl Biomater 2016;104:308-315.
24.
Chang Y, Goldberg VM, Caplan AI: Toxic effects of gentamicin on marrow-derived human mesenchymal stem cells. Clin Orthop Relat Res 2006;452:242-249.
25.
Ince A, Schutze N, Karl N, Lohr JF, Eulert J: Gentamicin negatively influenced osteogenic function in vitro. Int Orthop 2007;31:223-228.
26.
Rathbone CR, Cross JD, Brown KV, Murray CK, Wenke JC: Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res 2011;29:1070-1074.
27.
von Stechow D, Rauschmann MA: Effectiveness of combination use of antibiotic-loaded perossal with spinal surgery in patients with spondylodiscitis. Eur Surg Res 2009;43:298-305.
28.
Hajnoczky G, Csordas G, Das S, Garcia-Perez C, Saotome M, Sinha Roy S, Yi M: Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis. Cell Calcium 2006;40:553-560.
29.
Schwertz DW, Kreisberg JI, Venkatachalam MA: Gentamicin-induced alterations in pig kidney epithelial (LLC-PK1) cells in culture. J Pharmacol Exp Ther 1986;236:254-262.
30.
Rustenbeck I, Eggers G, Reiter H, Munster W, Lenzen S: Polyamine modulation of mitochondrial calcium transport. I. Stimulatory and inhibitory effects of aliphatic polyamines, aminoglucosides and other polyamine analogues on mitochondrial calcium uptake. Biochem Pharmacol 1998;56:977-985.
31.
Somermeyer MG, Knauss TC, Weinberg JM, Humes HD: Characterization of Ca2+ transport in rat renal brush-border membranes and its modulation by phosphatidic acid. Biochem J 1983;214:37-46.
32.
Sastrasinh M, Weinberg JM, Humes HD: The effect of gentamicin on calcium uptake by renal mitochondria. Life Sci 1982;30:2309-2315.
33.
Jiang Y, Jia T, Gong W, Wooley PH, Yang SY: Effects of Ti, PMMA, UHMWPE, and Co-Cr wear particles on differentiation and functions of bone marrow stromal cells. J Biomed Mater Res A 2013;101:2817-2825.
34.
Abu-Amer Y, Darwech I, Clohisy JC: Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007;9(suppl 1):S6.
35.
Elder S, Frankenburg E, Goulet J, Yetkinler D, Poser R, Goldstein S: Biomechanical evaluation of calcium phosphate cement-augmented fixation of unstable intertrochanteric fractures. J Orthop Trauma 2000;14:386-393.
36.
Gong T, Wang Z, Zhang Y, Zhang Y, Hou M, Liu X, Wang Y, Zhao L, Ruse ND, Troczynski T, Hafeli UO: A comprehensive study of osteogenic calcium phosphate silicate cement: material characterization and in vitro/in vivo testing. Adv Healthc Mater 2016;5:457-466.
37.
Goodman SB, Bauer TW, Carter D, Casteleyn PP, Goldstein SA, Kyle RF, Larsson S, Stankewich CJ, Swiontkowski MF, Tencer AF, Yetkinler DN, Poser RD: Norian SRS cement augmentation in hip fracture treatment. Laboratory and initial clinical results. Clin Orthop Relat Res 1998;348:42-50.
38.
Yetkinler DN, Ladd AL, Poser RD, Constantz BR, Carter D: Biomechanical evaluation of fixation of intra-articular fractures of the distal part of the radius in cadavera: Kirschner wires compared with calcium-phosphate bone cement. J Bone Joint Surg Am 1999;81:391-399.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.